The Sinopharm CNBG’s new protein vaccine has been approved for emergency use by the Ministry of Health and Prevention (MoHAP). The approval was made after monitoring and evaluating the study conducted on the vaccine by the UAE authorities.

The Ministry had earlier confirmed that the emergency use of the Sinopharm vaccine is compliant with the existing regulations. According to a statement released by the Ministry, the approved vaccine has shown improved immunity against SARS-CoV-2 variants while it can be stored and distributed with ease.

The study conducted at the UAE regarding this vaccine on volunteers who had received two doses of the Sinopharm CNBG’s inactivated vaccine has displayed greater immune response against newer COVID-19 variants.

Booster dose

The new vaccine will be produced and distributed by Hayat Biotech, a JV between G42 and Sinopharm CNBG, while the vaccine will be available to the public as a booster dose starting January 2022 as part of the measures taken to contain the virus spread.

This comes at a time when reports indicate that the UAE is the world's largest country in terms of the coverage rate of the Covid-19 vaccine, with over 22 million doses administered until December 23, 2021.

The ministry noted that the positive outcomes achieved of the Covid-19 vaccination campaign, and the commitment of community members to get vaccinated have been an important turning point in the fight against the virus, entering the recovery phase and returning to normal life.

The ministry emphasized the importance for community members to remain committed to preventive and healthy behaviors to preserve the gains and immunize the community from any evolved mutations.